PharmiWeb.com - Global Pharma News & Resources
01-Jul-2019

Immune-Mediated Inflammatory Diseases Treatment Market to surpass USD 153.5 Billion by 2024 | CAGR 6.3%

The Global Immune-Mediated Inflammatory Diseases Treatment Market is expected to grow steadily from USD 100.4 Billion in 2017 to USD 153.5 Billion in 2024, at a moderate CAGR of 6.3% from 2018 to 2024.

The Global Immune-Mediated Inflammatory Diseases Treatment Market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2018 to 2024. The report offers of historic and future market scenario in terms of market value, share and critical developments taking place in the industry. Market size, forecast, trends of each country and region are studied in the report for the focus period of 2018 to 2024.

We can provide sample pages for a better understanding of this report.
Request Sample of This Report @ http://www.amecoresearch.com/sample/12344

Qualitative assessment tools such as PEST analysis, cost structure analysis and regulatory compliance for pharmaceutical products are offered in the report. The report also comprises Pipeline Analysis which helps understand the comprehensive forecast scenario of the market in terms of value and dynamics. The report analyses the recent drug approval trends and market dynamics such as drivers, restrains, and opportunities, industry trends and future outlook in the Global Immune-Mediated Inflammatory Diseases Treatment Market.

The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market.

The market is studied for regions such as North America (U.S., and Canada), Europe (U.K., Germany, France, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East amp; Africa (GCC, South Africa, and Rest of Middle East amp; Africa).

Key Takeaways:

What is the market size in 2018 and the growth rate of the Global Immune-Mediated Inflammatory Diseases Treatment Market?

What is the market drivers, restrains, opportunities governing the Global Immune-Mediated Inflammatory Diseases Treatment Market?

Which are the largest and the fastest growing segments in the Global Immune-Mediated Inflammatory Diseases Treatment Market?

Who are the key players operating in the market and their market position?

What is the pipeline scenario, drug pricing analysis and technological development in the market?

View Detail Report With Complete Table Of Content@ http://www.amecoresearch.com/market-report/global-immunemediated-inflammatory-diseases-treatment-market-emr-12344

Factors propelling the growth of the market include growing number of inflammatory diseases, and advancement in drug development and therapies for treatment of immune mediated inflammatory disease. Moreover, increasing adoption of anti-inflammatory drugs, growing awareness among people, coupled with government initiative towards its treatment is further boosting the growth of the global immune mediated inflammatory diseases treatment market.

The years used for the assessment are as follows;

Historical year: 2014, 2015, 2016

Base year: 2017

Forecast period: 2018 ndash; 2024

RESEARCH METHODOLOGY

The research and analysis is based on the data and information obtained from various primary and secondary sources. The data obtained is validated by interacting with the companies of the concerned domain. The steps involved in the research methodology are;

Obtaining historical data of the market based on news, articles, publications, annual reports, white papers, surveys, and other secondary sources
Interacting with key opinion leaders of the market and developing data points based on interaction with them
Study of past trends in the market and their year on year Impact on the market size and share
Analyzing the collected data points
Bridging the data points to calculate the total global immune mediated inflammatory diseases treatment market and its various segments
Anticipating potential risks
Analyzing market forces such as drivers, restraints, and opportunities to assess new growth areas for the global immune-mediated inflammatory diseases treatment market
Finalizing the overall size and share of the global immune-mediated inflammatory diseases treatment market

OBJECTIVES:

To analyze market trends, opportunities, drivers, and restraints associated with the Immune Mediated Inflammatory Diseases market
To study market response with respect to the mergers and acquisitions in the industry
To profile key companies operating in the immune-mediated inflammatory diseases treatment market and provide their competitive landscape

MARKET SCOPE

The research scope for Immune-Mediated Inflammatory Diseases Treatment Market is as follows:

By Types of Diseases
Asthma
Chronic obstructive pulmonary diseases (COPD)
Inflammatory Bowel Disease (IBD)
Systemic lupus erythematosus (SLE)
Rheumatoid Arthritis (RA)
Psoriasis
Heart disease
Others

By Types of Drugs
Corticosteroids
Non-steroidal Anti-Inflammatory Drugs
Anti-TNF-alpha; agents
Others

By Therapies
Targeted biologic therapies
Novel therapies
Others

By End-User
Hospitals
Pharmacy Store
Online Pharmacy

By Region
North America
Latin America
Europe
Asia-Pacific
Middle East and Africa

FREE ANALYSIS

Global Immune-Mediated Inflammatory Diseases (IMIDs) Treatment market size is expected to reach, USD 153.5 Billion in 2024, at a CAGR of 6.3% from 2018 to 2024. Factors propelling the growth of the market include growing number of inflammatory diseases, and advancement in drug development and therapies for treatment of immune-mediated inflammatory diseases. Moreover, increasing adoption of anti-inflammatory drugs, growing awareness among people coupled with government initiatives towards its treatment is further boosting the growth of the global immune-mediated inflammatory diseases treatment market.

Immune-mediated inflammatory diseases (IMIDs), such as psoriasis, inflammatory bowel disease, rheumatoid arthritis, are chronic conditions affecting millions of people worldwide. Around 5% to 8% of the population in North America and Europe are affected by IMIDs. The growing awareness and understanding of the underlying pathogenesis and development in targeted biological therapies and immune modulators are the treatment options for many IMIDs. Various treatments available for IMIDs include systemic corticosteroids, immunosuppressant, biologic agents, and topical agents. Additionally, new clinical trials have provided strong evidence that targeted biological agent is highly effective and safer way to reduce inflammation and prevent tissue damage.

On the basis of Types of Diseases, the rheumatoid arthritis (RA) segment holds the largest share of the global immune-mediated inflammatory diseases treatment market in 2017 and is expected to grow at a significant growth rate during the forecast period due to growing number of elder people with chronic joints disorders, along with availability of biological therapeutic agents for the treatment.

Based on the Types of Drugs

The anti-TNF-alpha; agents segment holds the largest market share of the global IMIDs treatment market, due to the use of anti-TNF-alpha; agents in various inflammatory conditions
The non-steroidal anti-inflammatory drugs (NSAIDs) segment was the fastest growing segment of the global IMIDs treatment market in 2017, owing to growing number of people used NSAIDS for treatment of various inflammatory conditions
Geographically, North America holds the major share of global IMIDs treatment market in 2017, owing to growing incidence and prevalence of IMIDs, and increasing number of IMIDs patients in the U.S., coupled with advancements in the treatment of immune-mediated inflammatory diseases. Growth of IMIDs treatment market in Europe is mainly owing to growing awareness about its treatment coupled with availability of various treatment options in this region.

Key players in Immune-Mediated Inflammatory Diseases Treatment Market are GlaxoSmithKline, Eli Lilly, AstraZeneca, Bristol-Myers, Sanofi, Enlivex Therapeutics Ltd, F-Hoffmann-La-Roche, Enlivex Therapeutics Ltd, Immune Pharmaceuticals, and Tanabe Pharma Corporation

Table Of Contents

Global Immune-Mediated Inflammatory Diseases Treatment Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation amp; Forecast 2024

CHAPTER 1. Market Scope and Methodology

1.1. Market Definition

1.2. Market Segmentation

1.2.1. Market Breakdown, By Types of Diseases

1.2.2. Market Breakdown, By Types of Drugs

1.2.3. Market Breakdown, By Therapies

1.2.4. Market Breakdown, By End-User

1.2.5. Market Breakdown, By Region

1.3. Research Methodology

1.3.1. Initial Data Search

1.3.2. Secondary Research

1.3.3. Primary Research

1.3.4. Scope and Assumptions

1.4. Sources

1.5. Executive Summary

CHAPTER 2. Market Outlook

2.1. Introduction

2.2. Market Outlook

2.2.1. Opportunities

2.2.1.1. Advancement in drug development and therapies for treatment of immune-mediated inflammatory diseases

2.2.2. Trends

2.2.2.1. Growing awareness among people regarding the treatment of immune-mediated inflammatory diseases

2.2.2.2. Ongoing clinical research into immune-mediated inflammatory diseases

2.2.3. Growth Drivers

2.2.3.1. Growing number of inflammatory diseases

2.2.3.2. Increasing adoption of anti-inflammatory drugs

2.2.4. Impact Analysis of Drivers on Future Forecast of the Market

2.2.5. Restraints of the Market

2.2.5.1. Side effects of drugs

2.2.6. Impact Analysis of Restraints on Future Forecast of the Market

CHAPTER 3. Market Entry Strategy

3.1. Value Chain Analysis

3.2. Competitive Analysis

3.2.1. Company Market Share Analysis

3.2.2. Porterrsquo;s Five Forces Analysis

CHAPTER 4. Global Immune-Mediated Inflammatory Diseases Treatment Market Size and Forecast (2014 ndash; 2024)

4.1. Global Immune-Mediated Inflammatory Diseases Treatment Market, By Types of Diseases

4.1.1. Asthma

4.1.2. Chronic obstructive pulmonary diseases (COPD)

4.1.3. Inflammatory Bowel Disease (IBD)

4.1.4. Systemic lupus erythematosus (SLE)

4.1.5. Rheumatoid Arthritis (RA)

4.1.6. Psoriasis

4.1.7. Heart disease

4.1.8. Others

4.2. Global Immune-Mediated Inflammatory Diseases Treatment Market, By Types of Drugs

4.2.1. Corticosteroids

4.2.2. Non-steroidal Anti-Inflammatory Drugs

4.2.3. Anti-TNF-alpha; agents

4.2.4. Others

4.3. Global Immune-Mediated Inflammatory Diseases Treatment Market, By Therapies

4.3.1. Targeted biologic therapies

4.3.2. Novel therapies

4.3.3. Others

4.4. Global Immune-Mediated Inflammatory Diseases Treatment Market, By End-User

4.4.1. Hospitals

4.4.2. Pharmacy Store

4.4.3. Online Pharmacy

4.5. Global Immune-Mediated Inflammatory Diseases Treatment Market, By Region

4.5.1. North America

4.5.2. Latin America

4.5.3. Europe

4.5.4. Asia-Pacific

4.5.5. Middle East and Africa

CHAPTER 5. Global Immune-Mediated Inflammatory Diseases Treatment Market, By Geography

5.1. North America Immune-Mediated Inflammatory Diseases Treatment Market

5.1.1. North America Immune-Mediated Inflammatory Diseases Treatment Market, By Types of Diseases (USD Billion)

5.1.2. North America Immune-Mediated Inflammatory Diseases Treatment Market, By Types of Drugs (USD Billion)

5.1.3. North America Immune-Mediated Inflammatory Diseases Treatment Market, By Therapies (USD Billion)

5.1.4. North America Immune-Mediated Inflammatory Diseases Treatment Market, By End-User (USD Billion)

5.1.5. North America Immune-Mediated Inflammatory Diseases Treatment Market, By Country

5.1.5.1. The U.S.

5.1.5.2. Canada

5.1.5.3. Mexico

5.2. Latin America Immune-Mediated Inflammatory Diseases Treatment Market

5.2.1. Latin America Immune-Mediated Inflammatory Diseases Treatment Market, By Types of Diseases (USD Billion)

5.2.2. Latin America Immune-Mediated Inflammatory Diseases Treatment Market, By Types of Drugs (USD Billion)

5.2.3. Latin America Immune-Mediated Inflammatory Diseases Treatment Market, By Therapies (USD Billion)

5.2.4. Latin America Immune-Mediated Inflammatory Diseases Treatment Market, By End-User (USD Billion)

5.2.5. Latin America Immune-Mediated Inflammatory Diseases Treatment Market, By Country

5.2.5.1. Argentina

5.2.5.2. Brazil

5.2.5.3. Colombia

5.2.5.4. Rest of Latin America

5.3. Europe Immune-Mediated Inflammatory Diseases Treatment Market

5.3.1. Europe Immune-Mediated Inflammatory Diseases Treatment Market, By Types of Diseases (USD Billion)

5.3.2. Europe Immune-Mediated Inflammatory Diseases Treatment Market, By Types of Drugs (USD Billion)

5.3.3. Europe Immune-Mediated Inflammatory Diseases Treatment Market, By Therapies (USD Billion)

5.3.4. Europe Immune-Mediated Inflammatory Diseases Treatment Market, By End-User (USD Billion)

5.3.5. Europe Immune-Mediated Inflammatory Diseases Treatment Market, By Country

5.3.5.1. Germany

5.3.5.2. France

5.3.5.3. The U.K.

5.3.5.4. Italy

5.3.5.5. Spain

5.3.5.6. France

5.3.5.7. Monaco

5.3.5.8. Estonia

5.3.5.9. Rest of Europe

5.4. Asia-Pacific Immune-Mediated Inflammatory Diseases Treatment Market

5.4.1. Asia-Pacific Immune-Mediated Inflammatory Diseases Treatment Market, By Types of Diseases (USD Billion)

5.4.2. Asia-Pacific Immune-Mediated Inflammatory Diseases Treatment Market, By Types of Drugs (USD Billion)

5.4.3. Asia-Pacific Immune-Mediated Inflammatory Diseases Treatment Market, By Therapies (USD Billion)

5.4.4. Asia-Pacific Immune-Mediated Inflammatory Diseases Treatment Market, By End-User (USD Billion)

5.4.5. Asia-Pacific Immune-Mediated Inflammatory Diseases Treatment Market, By Country

5.4.5.1. China

5.4.5.2. Japan

5.4.5.3. Singapore

5.4.5.4. Australia

5.4.5.5. India

5.4.5.6. South Korea

5.4.5.7. New Zealand

5.4.5.8. Rest of Asia-Pacific

5.5. Middle East and Africa Immune-Mediated Inflammatory Diseases Treatment Market

5.5.1. Middle East and Africa Immune-Mediated Inflammatory Diseases Treatment Market, By Types of Diseases (USD Billion)

5.5.2. Middle East and Africa Immune-Mediated Inflammatory Diseases Treatment Market, By Types of Drugs (USD Billion)

5.5.3. Middle East and Africa Immune-Mediated Inflammatory Diseases Treatment Market, By Therapies (USD Billion)

5.5.4. Middle East and Africa Immune-Mediated Inflammatory Diseases Treatment Market, By End-User (USD Billion)

5.5.5. Middle East and Africa Immune-Mediated Inflammatory Diseases Treatment Market, By Country

5.5.5.1. Israel

5.5.5.2. Saudi Arabia

5.5.5.3. Ethiopia

5.5.5.4. Iran

5.5.5.5. Rest of Middle East and Africa

CHAPTER 6. Key Players and Strategic Developments

6.1. GlaxoSmithKline

6.1.1. Business Overview

6.1.2. Product and Service Offering

6.1.3. Financial Overview

6.1.4. SWOT Analysis

6.1.5. Strategic Developments

6.2. Eli Lilly

6.2.1. Business Overview

6.2.2. Product and Service Offering

6.2.3. Financial Overview

6.2.4. SWOT Analysis

6.2.5. Strategic Developments

6.3. AstraZeneca

6.3.1. Business Overview

6.3.2. Product and Service Offering

6.3.3. Financial Overview

6.3.4. SWOT Analysis

6.3.5. Strategic Developments

6.4. Bristol-Myers

6.4.1. Business Overview

6.4.2. Product and Service Offering

6.4.3. Financial Overview

6.4.4. SWOT Analysis

6.4.5. Strategic Developments

6.5. Sanofi

6.5.1. Business Overview

6.5.2. Product and Service Offering

6.5.3. Financial Overview

6.5.4. SWOT Analysis

6.5.5. Strategic Developments

6.6. F-Hoffmann-La-Roche

6.6.1. Business Overview

6.6.2. Product and Service Offering

6.6.3. Financial Overview

6.6.4. SWOT Analysis

6.6.5. Strategic Developments

6.7. Enlivex Therapeutics Ltd.

6.7.1. Business Overview

6.7.2. Product and Service Offering

6.7.3. Financial Overview

6.7.4. SWOT Analysis

6.7.5. Strategic Developments

6.8. Immune Pharmaceuticals

6.8.1. Business Overview

6.8.2. Product and Service Offering

6.8.3. Financial Overview

6.8.4. SWOT Analysis

6.8.5. Strategic Developments

6.9. Tanabe Pharma Corporation

6.9.1. Business Overview

6.9.2. Product and Service Offering

6.9.3. Financial Overview

6.9.4. SWOT Analysis

6.9.5. Strategic Developments

6.10. Abbreviation

Quick Buy This Premium Report From Here: http://www.amecoresearch.com/buy/12344

About Us:

Ameco Research is the one spot destination for all your research needs. Ameco Research holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.

Contact:

Email: sales@amecoresearch.com | +1 407 915 4157

Editor Details

Last Updated: 01-Jul-2019